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Abstract: Understanding protein interaction networks and their dynamic changes is a 
major challenge in modern biology. Currently, several experimental and in silico 
approaches allow the screening of protein interactors in a large-scale manner. Therefore, 
the bulk of information on protein interactions deposited in databases and peer-reviewed 
published literature is constantly growing. Multiple databases interfaced from user-friendly 
web tools recently emerged to facilitate the task of protein interaction data retrieval and 
data integration. Nevertheless, as we evidence in this report, despite the current efforts 
towards data integration, the quality of the information on protein interactions retrieved by 
in silico approaches is frequently incomplete and may even list false interactions. Here we 
point to some obstacles precluding confident data integration, with special emphasis on 
protein interactions, which include gene acronym redundancies and protein synonyms. 
Three human proteins (choline kinase, PPIase and uromodulin) and three different  
web-based data search engines focused on protein interaction data retrieval (PSICQUIC, 
DASMI and BIPS) were used to explain the potential occurrence of undesired errors that 
should be considered by researchers in the field. We demonstrate that, despite the recent 
initiatives towards data standardization, manual curation of protein interaction networks 
OPEN ACCESS 
Proteomes 2013, 1 4 
 
  
based on literature searches are still required to remove potential false positives. A three-step 
workflow consisting of: (i) data retrieval from multiple databases, (ii) peer-reviewed 
literature searches, and (iii) data curation and integration, is proposed as the best strategy to 
gather updated information on protein interactions. Finally, this strategy was applied to 
compile bona fide information on human DREAM protein interactome, which constitutes 
liable training datasets that can be used to improve computational predictions.  
Keywords: bioinformatics; calsenilin; choline kinase; data integration; DREAM; gene 
acronym; gene redundancy; HGNC; HUGO; human interactome; KChIP3; protein accession; 
protein interactions; protein-protein prediction; uromodulin 
 
1. Introduction 
In 1996, it was estimated that the human genome consists of 50,000–100,000 genes [1]. Far from 
the previous estimations, and in the light of the results from human sequencing projects [2,3], the 
current number of human protein-coding genes includes exactly 20,484 different entries [4] [updated 
from the HUGO Gene Nomenclature Committee (HGNC), May 2013]. The human genome is 
considered to be almost completely finished, meaning that the final number of protein-coding genes is 
not likely to increase significantly in the future and that the canonical sequence of each protein-coding 
gene is known. In parallel, the sequences of 20,249 different human protein products (the longest 
isoform produced after translation of each protein-coding gene) are also available (UniprotKB/  
Swiss-Prot, May 2013). On the one hand, the wealth of information available offers unprecedented 
opportunities towards data integration at the two different levels (genomics and proteomics). On the 
other hand, the bulk of information available seems insufficient to explain the complexity of humans. 
In this sense, the identification of protein interactions and their regulation may help to unravel novel 
and relevant information. This hypothesis relies on the fact that proteins do not exist as isolated entities 
inside cells, but perform their function(s) through the interaction with other molecules.  
The size and dynamics of the human interactome is currently unknown. As displayed in Table 1, 
different estimations on the number of protein-protein interactions in humans widely differ, ranging 
from ~13,000 to ~370,000. Even the definition of the term ―protein interaction‖ significantly varies 
among references (binary interactions or protein complexes, stable interactions versus weak or transient, 
predicted computational interactions without experimental validation may be considered, etc.).  
Although there is hardly a consensus on the number and validity of protein interactions, there is 
ample agreement on the idea that our understanding of the human interactome is in its early stages. 
Deciphering the interacting network of each individual protein and the conditions altering the 
interactome may be crucial to understanding their function and thus requires the integration of data 
available gathered from different sources including: (i) experimental data, (ii) prediction algorithms, 
(iii) database searches, and (iv) literature searches. 
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Table 1. Different estimations of the human interactome published in the literature 
including references and a brief description of the interactions. 
Human interactome 
[reference] 
publication year 
Description 
375,000 [5] 
2005 
These authors used literature-mining algorithms and then estimated the number 
of protein interactions assuming 25,000 human genes. 
154,000–369,000 [6] 
2006 
The authors quoted that their estimation includes protein complexes. 
650,000 [7] 
2008 
This estimation relies on data retrieved from Y2H 
a
 experiments and database 
searches. 
130,000 [8] 
2009 
This number of protein interactions exclusively considered binary interactions. 
13,217 
b
 [9] 
2012 
This estimation considered the longest protein isoform 
c
 of 20,846 human 
protein sequences. The size of the interactome was estimated using 
computational methods based on structural inference. The authors claimed that 
this estimation also includes self-interactions. 
a
 Y2H: yeast-two-hybrid; 
b
 Includes self-interactions and it is based on structural inferences; 
c
 See [10] for 
definitions on protein isoform and protein species. 
Regarding experimental data, three main experimental strategies allow for large-scale screening of 
protein networks, including yeast-two-hybrid (Y2H) experiments, co-immunoprecipitation or affinity 
purification, followed by mass spectrometry and protein arrays [11,12]. The biochemical principles 
underlying each experimental approach are different. Thus, it is well acknowledged that the three 
strategies may lead to the identification of different subsets of protein partners. For example, 
immunoprecipitation strategies lead to the identification of both directly and indirectly associated 
proteins (e.g., protein complexes) [11], whereas protein arrays typically focus on direct (also termed 
binary or physical) protein interactions [12]. Accordingly, multiple experimental approaches may be 
performed to screen for protein interactions and the results should be considered as complementary. 
A number of prediction algorithms and computational methods currently coexist and can be used to 
infer the occurrence of protein–protein interactions [13–19]. These algorithms rely on one or more 
features—such as genomic sequence, topological genomic clustering, protein sequence, protein 
structure, protein functional/structural domains or evolutionary relationship—and may also take 
advantage of known protein–protein interaction datasets to test, train, and improve the quality of their 
predictions. A comparative overview of prediction algorithms is beyond the scope of this report, but it 
is important to underline that computational algorithms frequently take advantage of reliable training 
datasets (i.e., bona fide list of protein interactions) to test and to improve their predictions.  
A range of databases currently allows the retrieval of information on protein interactions, including 
predictions of interactions and even modeling the pathways involved (reviewed in [20]). In this regard, 
it is important to distinguish databases compiling data from experimentally observed protein 
interactions from those reporting predictions without experimental evidence [21]. Another issue for 
consideration is that the list of candidate protein partners retrieved may significantly differ among 
databases, due to the fact that the amount and quality of the information deposited in each database are 
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not really comparable ([22] reviewed protein-protein interaction databases and their sources of 
information). The overall information overlap among databases is limited and, thus, gathering 
information from as many databases as possible may represent an advantage if thorough information 
on the interactome of a specific protein is the objective. This task currently constitutes an obstacle that 
may be prohibitive in terms of time. In order to facilitate interaction data retrieval from multiple 
databases, several web-based search engines such as PSICQUIC [23], DASMI [24] and BIPS [25] 
were recently developed and made publicly available for the scientific community. These web tools 
significantly simplify the screening of information. Nevertheless, relevant information affecting 
protein interactions is frequently overlooked [26] and, more importantly, still suffers from high rates of 
false positives and errors [9]. For that reason, literature searches on peer-reviewed journals still 
constitutes the main source of information on protein-protein interactions in two ways: first, literature 
searches may retrieve information that may not be included in databases and, second, the comparison 
of the list of protein interactors retrieved upon database searches and after literature searches enables 
manual correction of potential errors. To exemplify this, a recent report focusing on the identification 
of the Salmonella host interactome [26] compared the information available in >100 databases and 
>2,200 journal articles, leading to the identification of 62 protein-protein interactions of Salmonella 
proteins with human and mouse proteins, both acting as host for this bacteria. The authors stated that 
only six of these interactions were retrievable from databases and concluded that literature searches 
represented an essential step. In this sense, we strongly support that manual curation of protein-protein 
interactions based on literature searches is a requisite [27]. Indeed, in this report we point to several 
constraints hindering the fast integration of information on protein interactions, which support the need 
for curation strategies based on literature data. We also point out the main sources of errors that 
preclude fully automated protein-protein data retrieval: the proper use of standard acronyms, and the 
occurrence of acronym redundancies and synonyms that are arbitrarily used in the literature.  
2. Experimental  
2.1. Human Gene Consensus Sequences and Acronyms 
The updated list of human genes was adapted from the information provided by the National Center 
for Biotechnology Information [28]. This information is provided in this report as a comma separated 
values (CSV) (Supplementary File 1) and is also available in our public data repository at [29]. This 
file includes the complete list of protein-coding genes (20,484 entries) and pseudo genes (13,191 entries).  
2.2. Human Protein Consensus Sequences and Acronyms 
The consensus amino acid sequence of human proteins was retrieved from the Uniprot protein 
knowledgebase/Swiss-Prot [30]. The strategy used to retrieve this information consisted of the 
inclusion of the following string of keywords and Boolean connectors in the ―query‖ field of this 
database: organism: 9606 AND keyword: ―Complete proteome [KW-0181]‖ reviewed:yes. This string 
of characters retrieved 20,249 different human protein entries (May 2013) and can be used ad hoc for 
the retrieval of the updated list of human proteins. The list of proteins considered in this report is 
provided as a comma separated values (CSV) (Supplementary File 2) and can be downloaded from our 
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public data repository at [29]. Relevant information on the proteins such as protein description, Swiss-
Prot protein accessions and entries are also included. Protein accessions and entries represent unique 
and unambiguous identifiers for each protein (see [31] for further information). 
2.3. Database Searches and Protein Networking 
Protein networks and list of interacting proteins were carried out using PSICQUIC [23], DASMI [24] 
and BIPS [25]. These three search engines are representative examples of popular web-based tools 
frequently used by researchers in the field and able to merge protein interaction data combining the 
information deposited in multiple databases.  
2.4. Gene Redundancy 
The official gene acronyms and the corresponding synonyms accepted for each human gene were 
retrieved from UniProtKB (May 2013). Redundant symbols within gene names and synonyms were 
retrieved for each UniProtKB entry using case-sensitive comparison of all human symbols. A text file 
where each line represents alternative symbols used for a specific gene was prepared. For each line, 
redundant gene symbols were removed. That is, each line contains a non-redundant list of alternative 
symbols for a specific gene. From this per gene entry non-redundant list, a new redundant list of 
symbols was prepared where each line contains one symbol. The frequency of each symbol in this 
redundant list corresponds to the number of times a symbol refers to different genes and can 
conveniently be calculated using the ―table‖ command in the R statistical programming language. 
3. Results and Discussion 
3.1. Evidence for Erroneous Protein-Protein Interactions after Database Searches 
In this report, we demonstrate that searching for protein–protein interactions using in silico searches 
may lead to errors. To exemplify this, we first retrieved for human choline kinase (gene acronym: 
CHKA, accession: P35790, entry: CHKA_HUMAN) interactors using three web interfaces able to 
retrieve and integrate data from multiple source databases: PSICQUIC [23], DASMI [24] and BIPS [25]. 
In all cases, database searches were triggered using the human choline kinase Swiss-Prot accession 
(P35790, [32]).The Swiss-Prot accession acts as a unique and unambiguous identifier corresponding to 
a single protein product. Surprisingly, despite the unambiguity of the accession number submitted to the 
searches, we noticed that the three web engines listed one or more false protein interactors. As 
depicted in Figure 1 and Supplementary File 3, the list of wrong CHKA interactors included proteins 
such as regulator of chromosome condensation (gene acronym: RCC1, accession: P18754, entry 
RCC1_HUMAN) [33] and several casein kinases (CSNKs). Such errors could only be confirmed upon 
manual curation using experimental data published in peer-reviewed journals. Fortunately, information 
and/or links to citations containing original data are typically provided through search engines (see 
Supplementary File 3), facilitating their access to researchers. 
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Figure 1. Protein interaction network corresponding to human choline kinase (CHKA) 
using two different versions of STRING [34] versions 9.0 and 9.05. String may be 
accessed through it web interface [35] or selecting the corresponding option in PSICQUIC 
View [36]. Searches were triggered using the Swiss-Prot accession number P35790 [32], 
which uniquely identifies CHKA. The query protein (CHKA, depicted as a red sphere) 
appears connected with surrounding candidate interacting proteins. Left panel: database 
searches using STRING v9.0 retrieved false positive nodes A (RCC1, regulator of 
chromosome condensation) and B (casein kinase proteins -CSNKs- 1G2, 1D, 1A1, 1E, 
1AIL and 1G1). Right panel: a recent version of the software (STRING v.9.05) removed 
false positives and improved the quality of CHKA interactions. STRING also shows 
information on the source of the interaction mapped is also included as colored lines 
(databases, textmining and experimental evidence). The default scoring filtering criteria 
were selected in all cases. 
 
The example above clearly evidences that database queries may lead to errors, thereby allowing us 
to hypothesize that the source for such errors is the lack of consensus in the gene acronyms and protein 
abbreviations used to refer to human proteins. This hypothesis is based on the observation that casein 
kinases and choline kinase may be abbreviated in the scientific literature using the same abbreviation 
(i.e., CK). This was already detailed in a recent publication [37], quoting that up to five different 
abbreviations may be used to refer to the human choline kinase alpha gene (CHKA, CHK, CKI, CK 
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and EK) and they are all accepted as synonyms and are simultaneously and arbitrarily used in the 
literature. The lack of consensus in the use of gene acronyms may add confusion when searching for 
protein interactions. CHKA is exclusively attributed to choline kinase genes, CHK and CKI can be 
used to denote checkpoint kinases or casein kinase I, respectively. CHK may also refer to 
megakaryocyte-associated tyrosine kinase (CHK) and the three letter code ―CHK‖ is also included in 
the gene symbol used for choline kinase beta (CHKL). Similarly, two letter symbols (CK and EK) are 
included in a number of genes within the list, which contributes to add some noise.  
From the example above, it becomes obvious that the same string of characters used as 
abbreviations or acronyms may refer to different genes or gene products. We also demonstrate that 
such redundancy may lead to the inclusion of erroneous candidates among the list of protein interactors. 
Database builders and data integration initiatives are very aware that gene acronym redundancy 
may significantly undermine the quality of the list of interactions retrieved by in silico approaches. 
Indeed, as depicted in Figure 1, different versions of the same software may significantly differ since 
both data annotation and curation improve with time. In the absence of consensus, and given that 
multiple synonyms currently coexist in the literature, data curation is required. In this sense, ways to 
report the occurrence of errors from users to database builders should be implemented because the 
contribution from users may significantly foster the tedious task of data curation. 
3.2. The Redundancy of Gene Acronyms 
As quoted in the example above, one gene acronym may refer to different genes or gene products 
and such redundancy may lead to errors when identifying protein-protein interactions through 
automated database searches. Thus, we hypothesized that redundancy leads to ambiguity that 
constitutes the causal origin of mistakes, introducing erroneous protein interactors through in silico 
searches. This fact raised the question whether and to what extent such redundancy could be 
extrapolated to other proteins of interest. Therefore, we were prompted to investigate the frequency of 
gene acronym redundancy and its effect on the identification of protein–protein interactions. To that 
aim, we built a file (Supplementary File 1) containing the description and the gene acronyms of the 
20,484 human protein-coding genes. It is important to note that acronyms from the nomenclature 
authority and synonyms of each gene found in the literature are also included in the same file. All the 
acronyms and synonyms listed in Supplementary File 1 are accepted and arbitrarily used by authors in 
the literature. Therefore, this file likely constitutes the best resource for measuring the frequency of 
redundancy. We calculated the redundancy of gene names and synonyms and plotted the number of 
names referencing N different genes versus N genes referred (Figure 2). 
Interestingly, as displayed in Figure 2, the repetition of gene acronyms is a frequent event and a 
significant portion of the genes displayed redundancies ranging from two, up to ten. This plot 
evidences that one gene acronym may designate multiple genes and/or protein. Importantly, a 
significant percentage of gene acronyms may refer to two or more different genes. The gene acronym 
PPIASE constitutes a paradigmatic example of gene acronym redundancy since this is used to 
abbreviate the name of ten different protein-coding human genes (GeneIDs: 2080, 2081, 2086, 2287, 
2288, 2289, 8468, 11328, 51645, 51661 and 60681, all of them mapped on different gene locations) 
(Supplementary File 4). Obviously, such redundancy leads to undesired ambiguities and errors 
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introduced by database retrieval algorithms, which are unable to discern the attribution of a gene 
acronym to a certain gene or protein product. As explained above, the lack of consensus regarding the 
use of gene symbols may constitute a significant hurdle in the process of retrieving bona fide protein 
interactions from public repositories. On the other hand, using gene symbols to trigger searches in 
protein interaction repositories is a common practice. Moreover, the string of characters ―PPIAase‖ is 
also found in the description of a range of different human genes (see Supplementary File 4), 
contributing to extra confusion. 
Figure 2. Bar-plot demonstrating the redundancy displayed by human gene acronyms and their synonyms. 
 
As a result, we show that the probability of including false protein interactions after in silico 
searches using gene symbols is relatively high. This means that it is probable that using gene 
abbreviations as the only information included in database searches may end up showing interactions 
that do not strictly correspond to the protein of interest. Consequently, in order to discard potential 
errors, manual curation of the list of interactors retrieved using gene symbols against published data 
seems highly recommendable, especially in those cases where the frequency of the gene symbols used 
for a protein in the literature is ≥2. 
Regarding proteins, in a previous section using choline kinase as an example, we showed that one 
protein may correspond to multiple gene acronyms. As a means to preclude such ambiguity, the 
UniprotKB/Swiss-Prot database uses two different types of alphanumerical identifiers for each protein 
entry: accession and entry names [38]. Accessions are composed of six consecutive alpha-numerical 
characters without spaces or special characters and constitute stable and unique identifiers for each 
protein. These are stable identifiers and should be used to cite UniprotKB/Swiss-Prot entries. Upon 
integration into UniprotKB/Swiss-Prot, each entry is assigned a unique accession, which is called 
―Primary (citable) accession.‖ 
Probably the best way to circumvent the ambiguity problem caused by gene acronym redundancies 
would be using consensus lists of gene acronyms exclusively attributed to single genes (not shared by 
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any other gene) [4]. Nevertheless, as exemplified above, manual curation of metadata seems necessary 
to preclude unnecessary errors. In the meantime, we provide here an open-access standalone software 
tool termed ―Gene Symbol Redundancy Checker‖ to facilitate validation of gene redundancies [39]. 
This software runs under Windows (32-bit or 64-bit systems, downloadable as zip compressed file) 
and calculates the degree of symbol redundancy for a list of gene symbols pasted into the application. 
This can, for example, be a list of genes in a network provided by an online tool. The output also 
summarizes all alternative symbols for all the genes that share a given gene symbol. The output can be 
subsequently exported or copy and pasted to any spreadsheet data-processing software for further analysis. 
3.3. Protein Accessions, Protein Entries and Database Searches 
Several databases may be used for proteomic research and their selection mainly depends on the 
quality of protein annotation and on objective pursued. In this regard, the Swiss-Prot protein database 
is widely considered as the ―gold standard‖ for proteomic approaches because it contains high-quality 
and manually annotated data, as well as the sequence of the proteins and access to protein-protein 
interaction data. Remarkable efforts were carried out in the past and others are under way towards the 
convergence, integration and standardization of the bulk of the data available in different protein 
databases. For instance, in 2011, the Swiss-Prot database incorporated the information of the human 
International Protein Index database (further information in this link [40]), a database frequently used 
in the past decade for proteomic experiments. It is evident, therefore, that protein databases rapidly 
evolve. Improved versions are continuously released and the descriptions of the proteins included in 
them also vary with time. In the case of the Swiss-Prot database, such changes are listed in The 
UniprotKB/Swiss-Prot Sequence/Annotation Version Archive (UniSave). 
For that reason, every protein included in the Swiss-Prot database is characterized by at least one 
protein accession and one protein entry that are exclusively attributed to a known protein product. 
Proteins characterized by more than one accession may be included in Swiss-Prot. For example, 
uromodulin (gene acronym: UMOD, accession: P07911, entry: UROM_HUMAN) was associated in 
the past with four different Swiss-Prot accessions (P07911, Q540J6, Q6ZS84 and Q8IYG0, Swiss-Prot 
v57.15). Currently, only the first accession is accepted (P07911), but previous accession numbers still 
appear in the literature, contributing to the confusion. Regarding protein descriptions and continuing 
with the same example, uromodulin is also frequently referred to as the Tamm-Horsfall protein. The 
latter term is frequently used in medical literature for historical reasons because it was first purified 
from the urine of healthy individuals by Tamm and Horsfall [41,42]. It is important to underline that 
the two descriptions are correct and synonymous, but their arbitrary use in the literature complicates 
the integration of data and may hamper thorough retrieval of protein interactions.  
The trend towards data simplification and integration is evident, and the number of initiatives 
aiming overall integration of -omic(s) data is under way, but it is still not sufficient. As an example, a 
recent web-based application termed KUPKB (Kidney and Urinary Pathway Knowledge Base) offers 
access to data from multiple -omic approaches [43]. To reiterate, the lack of consensus to name genes 
and proteins significantly obstructs data integration. As a proof of principle, in a previous report, we 
built a consensus list of proteins found in human urine. This objective required the integration of proteomic 
metadata previously published and the combination of a list of proteins identified independently in 
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different laboratories during the last decade [44]. Previously, we demonstrated that integrating and 
updating previous metadata may be a tedious task but it is necessary for data integration. 
Accordingly, in order to promote automated data integration, the lists of proteins identified by 
proteomic experimental approaches should include primary accessions and/or entries exactly in the 
form they appear in the Swiss-Prot database and, if possible, the corresponding gene acronym as 
recommended by the HUGO Gene Nomenclature Committee. Similarly, the use of recommended 
protein names exactly as they appear in the Swiss-Prot database should be promoted, since this could 
significantly simplify database searches whilst reducing ambiguity at the same time. 
3.4. Database Searches Fail to Include Dynamic Changes on Protein Networks 
The retrieval of the overall list of interactors for a specific protein of interest is essential to 
discerning novel from previous findings and also serves to identify the pathways involved. In the 
sections above we quoted some problems affecting the number and quality of interactors retrieved by 
searching in multiple databases and the need to complete and curate that information by comparing the 
list of interactors with published literature. However, the interactome of a given protein of interest is 
not static and adapts to changes in the environmental conditions. Thus, understanding the dynamics or 
protein interaction networks is crucial to unraveling the role and the regulation of proteins under 
different cellular conditions [45]. Here, we briefly point to the fact that in silico database searches 
typically fail to provide information on protein interaction changes as a response to modifications in 
the experimental conditions. To exemplify this, we used human calsenilin (gene acronym: KCNIP3, 
accession: Q9Y2W7, entry: CSEN_HUMAN), a protein of interest in our lab that was originally 
identified as calsenilin—a Ca2+-binding protein belonging to the family of neuronal calcium sensor 
proteins [46]. Shortly thereafter, this protein was found to be identical to the Ca
2+
-dependent gene 
silencer DREAM (downstream regulatory element antagonist modulator) [47] and, later, to one of the 
interacting proteins (KChIPs)—or -subunits—of the voltage-gated Kv channels, KChIP3 [48]. The 
three descriptions correspond to the same protein, since it is the product of a single gene, and localizes 
to three different cellular compartments (membrane, cytoplasm and nucleus). In these three cellular 
locations, DREAM plays different roles (K
+
 channel, Ca
+2
 binding protein and transcriptional 
repressor, respectively) and interacts with different subsets of molecules—including the interaction 
with DNA in the nucleus [49]. At structural level, DREAM harbors four EF-hand domains able to bind 
Ca
+2
 ions that provoke structural changes. Thus, it is foreseeable that the DREAM interactome 
significantly varies depending on sub-cellular localization or the presence/absence of Ca
+2
. It is 
important to underline that none of the databases tested—including 22 databases focused on protein-
protein interactions available at [22,50] or integrated web-based platforms like PSICQUIC [23], 
DASMI [24] and BIPS [25]—offered direct information about DREAM interactome changes or 
provided clues on factors modifying or affecting DREAM networking. Conversely, a good deal of 
information can be extracted from published literature (for review see [51]). Thus, we decided to 
compile the current status of DREAM interactome (Table 2) including supporting references, year of 
publication, in vitro and in vivo models used in the experiments, human gene acronyms (including 
synonyms), UniprotKB/Swiss-Prot accessions and entries, description, techniques used for detection of 
the interactions. Further information influencing DREAM interactions is also included, such as the 
potential effect of Ca
+2
 and post-translational modifications. 
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Table 2. DREAM interactome: publication year, experimental model used, corresponding human gene acronyms (May 2013), Swiss-Prot 
protein accessions release 2013_05 (May-2013), protein entries, protein descriptions and synonyms, detection method used and other 
additional relevant information is also included. 
Year 
Ref. 
Experimental model 
used 
HUMAN GENE 
ACRONYM  
HUGO acronym (bold), 
other synonyms 
Human Swiss-Prot 
accession, entries 
Protein description 
and synonyms 
Detection method Additional information 
1998 
[46] 
in vitro: Y2H, PSEN as 
bait and human brain 
cDNA. 
in vitro: COS-7 cells. 
PSEN1,FAD, PS1, S182,  
PS-1, AD3 
P49768 
PSN1_HUMAN 
Presenilin-1, Protein S182. 
Y2H and co-precipitation 
followed by Western blot. 
Y2H experiments included in this 
report could not confirm PSEN2–
DREAM interaction. 
1998 
[46] 
 
2008 
[52] 
in vitro: Y2H, PSEN as 
bait and human brain 
cDNA. 
in vitro: COS-7 cells. 
in vitro: SH-SY5Y cells. 
PSEN2, AD3L, PS2, STM2, 
AD4, CMDV1 
P49810 
PSN2_HUMAN 
Presenilin-2, AD3LP, AD5, E5-1, 
STM-2. 
Co-localization in COS-7 
cells and co-precipitation 
followed by Western blot.  
Co-transfection,  
co-precipitation followed 
by Western blot 
Y2H experiments were not able to 
confirm PSEN2-DREAM 
interaction. 
This interaction occurs in a Ca+2-
independent manner. 
1996 
[47] 
1999 
[53] 
2011 
[54] 
in vitro: CHO cells. 
in vitro: HEK 293 cells. 
in vitro: CHO cells. 
KCNIP3, CSEN, DREAM, 
KCHIP3 
Q9Y2W7, 
CSEN_HUMAN 
Calsenilin, A-type potassium 
channel modulatory protein 3, 
DRE-antagonist modulator 
(DREAM), Kv channel-interacting 
protein 3 (KCHIP3) 
Molecular mass from 
SDS-PAGE gels and 
Western blot. 
Multimeric forms (monomers [47], 
dimers [47,54] and tetramers 
[47,53] described). 
2000 
[53] 
in vitro: HEK293, NB69, 
SK-NMC cells. 
CREM, CREM-2, ICER, 
hCREM-2 
Q03060 
CREM_HUMAN 
cAMP-responsive element 
modulator, inducible cAMP early 
repressor (ICER). 
Pull-down using CREM 
as bait. 
DREAM–CREAM protein-protein 
interaction leads to loss of binding 
of the transcriptional repressor 
DREAM to target genes [53]. 
2000 
[48] 
in vitro: Y2H, KCNIP4 
as baits. 
KCNIP4, CALP, KCHIP4 
Q6PIL6 
KCIP4_HUMAN 
Kv channel-interacting protein 4 
(KChIP4), A-type potassium 
channel modulatory protein 4, 
Calsenilin-like protein, Potassium 
channel-interacting protein 4. 
Y2H and co-precipitation. 
Y2H cDNA library was 
constructed from polyA+ RNA 
extracted from rat brain. 
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Table 2. Cont. 
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HUMAN GENE 
ACRONYM  
HUGO acronym (bold), 
other synonyms 
Human Swiss-Prot 
accession, entries 
Protein description 
and synonyms 
Detection method Additional information 
2002 
[55] 
in vivo: rat brain nuclear 
extract. 
in vitro: HEK293, PC12 
cells. 
CREB1, CREB 
P16220 
CREB1_HUMAN 
Cyclic AMP-responsive element 
binding protein 1. 
Immunoprecipitation 
from brain nuclear 
extracts using anti-
DREAM antibody. 
DREAM–CREB1 protein-protein 
interaction prevents recruitment of 
CBP by phospho-CREB and affects 
CRE-dependent transcription. 
2004 
[56] 
in vivo: thyroid-derived 
FRTL-5 cells. 
in vitro: co-
immunoprecipitation in 
CHO cells. 
NKX2-1, BCH, BHC, NK-2, 
NKX2.1, NKX2A, 
TEBP,TITF1,TTF-1, TTF1 
P43699 
NKX21_HUMAN 
Homeobox protein Nkx-2.1, 
Homeobox protein NK-2 
homolog A, Thyroid nuclear 
factor 1, Thyroid transcription 
factor 1. 
Co-precipitation using 
GST-DREAM as bait in 
FRTL-5 thyroid-derived 
cells. 
DREAM regulates the expression of 
the thyroglobulin gene. 
2005 
[57] 
2008 
[58] 
in vitro: co-incubation 
query protein (GST-
DREAM) and bait 
protein (6His-VDR). 
VDR, NR1/1 
P11473 
VDR_HUMAN 
Vitamin D3 receptor,  
1,25-dihydroxyvitamin D3 
receptor, Nuclear receptor 
subfamily 1 group I member 1. 
Pull-down after 
incubation of Ni-
Sepharose beads with a 
1:1 protein mixture of 
GST-DREAM  
(Δ65-256) and 6His-VDR. 
Ca2+ induces dimerization of DREAM 
and a binding interaction between 
DREAM and VDR. 
Chromatin immunoprecipitation 
showed that DREAM also binds to 
DNA, acting as a transcriptional 
regulator on vitamin D and retinoic 
acid response elements. 
2006 
[59] 
in vitro: Y2H, DREAM 
as bait. 
in vitro: co-
immunoprecipitation in 
H4 cells. 
CtBP1,CTBP 
Q13363 
CTBP1_HUMAN 
C-terminal-binding protein 1. 
Y2H using N-terminus 
of DREAM as bait and 
co-precipitation. 
DREAM–CTBP may modulate 
transcriptional repression of c-fos. 
2006 
[59] 
in vitro: Y2H, DREAM 
as bait. 
in vitro: co-
immunoprecipitation in 
H4 cells. 
CtBP2, ribeye 
P56545 
CTBP2_HUMAN 
C-terminal-binding protein 2. 
Y2H using N-terminus 
of DREAM as bait and 
co-precipitation. 
DREAM–CTBP may modulate 
transcriptional repression of c-fos. 
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2007 
[60] 
in vitro: Y2H, DREAM 
as bait. 
in vitro: co-
immunoprecipitation in 
PC12 cells. 
in vitro: DREAM Ser95 
phosphorylation using 
HEK293. 
GRK6, GPRK6 
P43250 
GRK6_HUMAN 
G protein-coupled receptor 
kinase 6, G protein-coupled 
receptor kinase GRK6. 
Y2H and confirmed by 
co-precipitation of 
PC12 cell extracts and 
antibodies specific for 
GRK6. 
A mutated DREAM insensitive to 
Ca+2was used to preclude potential 
artifacts in Y2H screening.  
2007 
[60] 
in vitro: Y2H, DREAM 
as bait. 
in vitro: co-
immunoprecipitation 
using PC 12 cells. 
in-vitro: DREAM Ser95 
phosphorylation using 
HEK293. 
ADRBK1, BARK1, BETA-
AEK1,GRK2 
P25098 
ARBK1_HUMAN 
Beta-adrenergic receptor kinase 1, 
G-protein coupled receptor kinase 
2. 
Co-precipitation of PC12 
cell extracts and 
antibodies specific for 
GRK6. 
May regulate DREAM function 
through phosphorylation. 
2008 
[61] 
in vitro: Y2H, mouse 
G3GALT2 as bait and 
human brain cDNA. 
in vitro: co-
immunoprecipitation in 
CHO-K1 cells. 
B3GALT2, BETA3GALT2, 
GLCT2, beta3Gal-T2 
O43825 
B3GT2_HUMAN 
Beta-1,3-galactosyltransferase 2, 
Beta-1,3-GalTase 2, UDP-
galactose:2-acetamido-2-deoxy-D-
glucose 3beta-
galactosyltransferase 2. 
Y2H using N-terminus of 
GalT2 as bait. 
DREAM is involved in the 
trafficking of glycosyl-transferases 
to Golgi and endoplasmic 
reticulum. 
2009 
[62] 
in vivo: thyroid glands 
from mice. 
in vitro: co-
immunoprecipitation in 
CHO cells. 
TSHR, CHNG1, LGR3, 
hTHSR-1 
P16473 
TSHR_HUMAN 
Thyrotropin receptor, Thyroid-
stimulating hormone receptor. 
Co-immunoprecipitation 
using mice thyroid protein 
extracts and cells 
transfected with 
hemagglutinin-tagged 
DREAM. 
Activation of cAMP signaling 
pathway, thyroid enlargement and 
nodular development. 
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2010 
[63] 
in vivo: co-
immunoprecipitation 
using mouse 
hippocampal extracts. 
DLG4, PSD-95, PSD95, 
SAP-90, SAP90 
P78352 
DLG4_HUMAN 
Disks large homolog 4, 
Postsynaptic density protein 95, 
Synapse-associated protein 90. 
Co-immunoprecipitation. 
DREAM modulates the function of 
postsynaptic NMDA receptor, 
synaptic plasticity, behavioral 
learning and memory. 
2010 
[64] 
in vivo: co-
immunoprecipitation 
using rat brain extracts. 
CACNA1H, Cav3.2 
O95180 
CAC1H_HUMAN 
Voltage-dependent T-type 
calcium channel subunit alpha-
1H, Low-voltage-activated 
calcium channel alpha1 3.2 
subunit, Voltage-gated calcium 
channel subunit alpha Cav3.2 
Co-immunoprecipitation. Rat brain protein extracts. 
2010 
[64] 
in vivo: co-
immunoprecipitation 
using rat brain extracts. 
CACNA1I, Cav 3.3, 
KIAA1120 
Q9P0X4 
CAC1I_HUMAN 
Voltage-dependent T-type 
calcium channel subunit alpha-
1I, Voltage-gated calcium 
channel subunit alpha Cav3.3. 
Co-immunoprecipitation. Rat brain protein extracts. 
2010 
[65] 
in vitro: co-
immunoprecipitation in 
HEK293 cells. 
in vivo: co-
immunoprecipitation in 
rat hippocampus extracts. 
GRIN1, GluN1, NR1, 
NMDAR1, NMDR1 * 
Q05586 
NMDZ1_HUMAN 
Glutamate receptor ionotropic, 
Glutamate [NMDA] receptor 
subunit zeta-1, N-methyl-D-
aspartate receptor subunit NR1. 
Immunoprecipitation 
from rat hippocampus 
extracts. 
This interaction supports the role of 
DREAM in learning and memory. 
2011 
[66] 
in vitro: Y2H, DREAM 
as bait and human brain 
cDNA. 
in vitro: co-
immunoprecipitation in 
PC12 and HEK293 cells. 
UBE2I, C358BE.1, P18, 
UBC9 
P63279 
UBC9_HUMAN 
SUMO-conjugating enzyme 
UBC9, SUMO-protein ligase, 
Ubiquitin carrier protein 9 
Ubiquitin carrier protein I, 
Ubiquitin-conjugating enzyme 
E2, Ubiquitin-protein ligase I, 
p18. 
Y2H and co-
immunoprecipitation of 
PC12 cell protein 
extracts. 
Sumoylation regulates nuclear 
localization of DREAM. A mutated 
DREAM insensitive to Ca+2 was 
used to preclude potential artifacts 
in Y2H screening. 
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2011 
[54] 
in vitro: Y2H, Ca+2 
insensitive DREAM as 
bait and human bone 
marrow cDNA. 
in vitro: co-
immunoprecipitation in 
COS-7 cells. 
Prdx3,AOP-1, AOP1, 
HBC189, MER5, PRO1748, 
SP-22, Prx-III 
P30048 
PRDX3_HUMAN 
Thioredoxin-dependent 
peroxidereductase, mitochondrial, 
Antioxidant protein 1, HBC189, 
Peroxiredoxin III, Peroxiredoxin-3, 
Protein MER5 homolog. 
Y2H and co-
immunoprecipitation of 
CHO cell protein 
extracts. 
Prdx3 is a mitochondrial protein. 
Unlikely to mediate the regulation 
of DREAM under basal conditions. 
The subcellular compartment 
where the redox regulation of 
DREAM in vivo takes place not yet 
characterized. 
2012 
[67] 
in vivo: co-
immunoprecipitation 
using rat brain extracts. 
CALM1,CAMI, 
CPVT4,DD132, PHKD, 
caM,CALML2 
P62158 
CALM_HUMAN 
Calmodulin. 
Affinity capture followed 
by mass spectrometric 
identification of 
interacting proteins. 
In the presence of Ca+2, DREAM 
binds to calmodulin. A list of 
proteins potentially binding to 
DREAM under Ca+2-dependent and 
independent conditions is included 
in [67]. 
2012 
[67] 
in vivo: co-
immunoprecipitation 
using rat brain extracts. 
PPP3R1, CALNB1, CNB, 
CNB1 
P63098 
CANB1_HUMAN 
Calcineurin subunit B type 1, 
Protein phosphatase 2B regulatory 
subunit 1, Protein phosphatase 3 
regulatory subunit B alpha isoform 
1. 
Affinity capture and 
mass spectrometric 
identification of 
interacting proteins. 
In the absence of Ca+2, DREAM 
binds to calcineurin subunit-B.  
A list of proteins potentially 
binding to DREAM under Ca+2-
dependent and independent 
conditions is included in [67]. 
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4. Conclusions 
The study of protein interactomes and the pathways involved is a major objective currently pursued. 
The overall understanding of protein networks requires gathering and merging information from 
multiple sources (large-scale experiments, multiple data repositories and published literature) but 
compilation of protein interactions still constitutes a major current bottleneck. Different methodologies 
currently enable the generation of large bulks of data, and a plethora of databases are continuously fed 
with novel data. It is important to highlight that despite the rapid advances towards data integration and 
standardization, integration of interaction data from in silico sources is an error-prone task and, thus, 
requires manual data curation.  
Here, we pointed to two sources of ambiguities that promote the accumulation of errors: gene 
acronym redundancies and protein description synonyms. We take advantage of several proteins of 
interest in our group to exemplify the occurrence of such ambiguities and to evidence that arbitrary 
ways to name human genes and proteins undermine fully automated and reliable data integration. 
We emphasize that gene acronym redundancies constitutes a frequent event. A significant number 
of gene acronyms suffer some degree of redundancy, which probably constitutes the most significant 
hurdle towards data integration. In parallel, at the protein level, it is obvious that different authors refer 
to the same proteins using different acronyms arbitrarily chosen. These two sources of ambiguities  
lead to errors, especially when using bioinformatics and data-mining algorithms for the retrieval of 
protein interactions.  
Initiatives such as the Human Proteome Organization Proteomics Standards Initiative (HUPO  
PSI-MI) focused on the need for data format standardization and proposed the incorporation of 
controlled vocabularies to facilitate data exchange and integration (see [27] for review). Despite the 
ongoing efforts, the list of potential interactors retrieved through bioinformatic tools still lacks 
reliability and requires confirmation of data through literature searches. The last statement is especially 
true assuming that protein-protein interactions available in databases will be always behind state-of-
the-art information described in the literature. Moreover, looking for interactions in the literature may 
be advantageous in several ways: first, it may provide valuable interactions not included in databases; 
second, it is the best way to find detailed information on the experimental conditions favoring the 
interactions and the techniques used to identify them; and, finally, scientific articles serve as a basis for 
data curation.  
We applied the recommendations provided in this report to explore the current status of the human 
DREAM interactome. Updated information on this protein is tabulated in this report, including the list 
of interactors retrieved from databases and confirmed upon manual data screening based on supporting 
peer-reviewed literature. The DREAM interactome can, thus, be further exploited for drug discovery 
approaches and serves as a bona fide ―training-set‖ for future improvements of protein-protein 
prediction algorithms. 
To summarize, we propose the use of standard unambiguous gene acronyms and/or protein 
accessions in published literature and in electronic data repositories as the best way to promote data 
integration and to minimize the possibility of errors in the task of retrieving protein-protein 
interactions from databases. The use of unique gene and protein identifiers should be promoted by 
editorials and, if possible, in a retrospective manner (by including suitable gene and/or protein 
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descriptions and abbreviations in those articles previously published). In our opinion, this could be the 
best way to foster data integration while ameliorating the tedious task of manually reviewing, 
extracting data and filtering out errors based on published data. This rationale is supported by the fact 
that once published, it is hardly possible to include changes, including designation and abbreviation of 
genes and proteins. In our opinion, our proposal is certainly feasible, since a list of unambiguous gene 
acronyms and protein accessions are already available from the HUGO Gene Nomenclature 
Committee (HGNC) and UniprotKB/Swiss-Prot). A clear and concise specification of the source of 
gene description and abbreviation may facilitate future data integration strategies, including the 
identification of protein interactions. Therefore, we propose that the source of genes and/or proteins 
used and their corresponding abbreviations should be clearly quoted in publications, including 
sentences such as: ―Human gene names, description and abbreviations used in this report follow the 
recommendations from the HUGO Gene Nomenclature Committee (HGNC),‖ or ―Human protein names, 
description and abbreviations follow the recommendations from the UniprotKB/Swiss-Prot database.‖  
Electronic Supplementary Material 
Supplementary File 1. Full list of human genes, acronyms and description included in the National 
Center for Biotechnology Information. The list includes protein-coding genes, pseudo genes and  
non-coding RNA. The updated list of genes can be downloaded using the file transfer protocol (FTP) 
from the NCBI at [68]. 
Supplementary File 2. Full list of human proteins, accession, entries and descriptions included in the 
Uniprot protein knowledgebase/Swiss-Prot (UniprotKB/Swiss-Prot). Each human protein contained in 
this database is represented by one unique UniProtKB/Swiss-Prot accession and one entry (for further 
information see [31]. The updated list of human proteins can be retrieved using the following strings in 
the ‗query‘ field: organism:9606 AND keyword: ―Complete proteome [KW-0181]‖ reviewed:yes. 
Supplementary File 3. Human choline kinase protein-protein interactions retrieved in databases using 
three different web interfaces: PSICQUIC View [36], DASMI [69] and BIPS [70]. In all cases, the 
search was triggered by introducing the UniprotKB/Swiss-Prot accession P35790 [32] as unique 
identifier for human choline kinase. RCC1 (regulator of chromosome condensation) was included 
among the list of candidates in all cases (highlighted in red), but this protein is a false positive and 
constitutes an error of database searches, as derived from [33] reporting the interaction between RCC1 
and casein kinase I. The list of candidate interacting proteins, accessions (where available), supporting 
publications and the source (database) of information are included.  
Supplementary File 4. Paradigmatic example of gene acronym redundancy. The use of the gene 
acronym PPIASE (or PPIase) can be found in the literature to abbreviate the name often different 
protein-coding human genes (GeneIDs: 2080, 2081, 2086, 2287, 2288, 2289, 8468, 11328, 51661 and 
60681) mapped on different gene locations. The string of characters 'PPIASE' is also included in the 
description of a range of different proteins (highlighted in red). 
  
Proteomes 2013, 1 20 
 
  
Acknowledgments 
J. Casado-Vela is a JAE-DOC (CSIC) holder supported by Ministerio de Economía y 
Competitividad, Spain, co-funded by the European Social Fund. RM is supported by PTDC/EIA-
EIA/099458/2008 Fundação para a Ciência e a Tecnologia (FCT), program CIENCIA 2007. Human 
gene names, description and abbreviations used in this report follow the recommendations from the 
HUGO Gene Nomenclature Committee (HGNC). Human protein names, description and abbreviations 
follow the recommendations from the UniprotKB/Swiss-Prot database. We thank HUGO and 
UniprotKB/Swiss-Prot for their effort in gene and protein standardization. 
Conflict of Interest 
The authors declare no conflict of interest. 
References and Notes 
1. Schuler, G.D.; Boguski, M.S.; Stewart, E.A.; Stein, L.D.; Gyapay, G.; Rice, K.; White, R.E.; 
Rodriguez-Tome, P.; Aggarwal, A.; Bajorek, E.; et al. A gene map of the human genome. Science 
1996, 274, 540–546. 
2. Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.;  
Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. 
Nature 2001, 409, 860–921. 
3. Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W.; Mural, R.J.; Sutton, G.G.; Smith, H.O.; 
Yandell, M.; Evans, C.A.; Holt, R.A.; et al. The sequence of the human genome. Science 2001, 
291, 1304–1351. 
4. Gray, K.A.; Daugherty, L.C.; Gordon, S.M.; Seal, R.L.; Wright, M.W.; Bruford, E.A. 
Genenames.org: the HGNC resources in 2013. Nucleic Acids Res. 2013, 41, D545–D552. 
5. Ramani, A.K.; Bunescu, R.C.; Mooney, R.J.; Marcotte, E.M. Consolidating the set of known 
human protein-protein interactions in preparation for large-scale mapping of the human 
interactome. Genome Biol. 2005, 6, R40. 
6. Hart, G.T.; Ramani, A.K.; Marcotte, E.M. How complete are current yeast and human protein-
interaction networks? Genome Biol. 2006, 7, e120. 
7. Stumpf, M.P.; Thorne, T.; de Silva, E.; Stewart, R.; An, H.J.; Lappe, M.; Wiuf, C. Estimating the 
size of the human interactome. Proc. Natl. Acad. Sci. USA 2008, 105, 6959–6964. 
8. Venkatesan, K.; Rual, J.F.; Vazquez, A.; Stelzl, U.; Lemmens, I.; Hirozane-Kishikawa, T.; Hao, 
T.; Zenkner, M.; Xin, X.; Goh, K.I.; et al. An empirical framework for binary interactome 
mapping. Nat. Methods 2009, 6, 83–90. 
9. Tyagi, M.; Hashimoto, K.; Shoemaker, B.A.; Wuchty, S.; Panchenko, A.R. Large-scale mapping 
of human protein interactome using structural complexes. EMBO Rep. 2012, 13, 266–271. 
10. Casado-Vela, J.; Cebrian, A.; Gomez del Pulgar, M.T.; Sanchez-Lopez, E.; Vilaseca, M.; 
Menchen, L.; Diema, C.; Selles-Marchart, S.; Martinez-Esteso, M.J.; Yubero, N.; et al. Lights and 
shadows of proteomic technologies for the study of protein species including isoforms, splicing 
variants and protein post-translational modifications. Proteomics 2011, 11, 590–603. 
Proteomes 2013, 1 21 
 
  
11. Braun, P.; Tasan, M.; Dreze, M.; Barrios-Rodiles, M.; Lemmens, I.; Yu, H.; Sahalie, J.M.; 
Murray, R.R.; Roncari, L.; de Smet, A.S.; et al. An experimentally derived confidence score for 
binary protein-protein interactions. Nat. Methods 2009, 6, 91–97. 
12. Casado-Vela, J.; Gonzalez-Gonzalez, M.; Matarraz, S.; Martínez-Esteso, M.J.; Vilella, M.; 
Sayagues, J.M.; Fuentes, M.; Lacal, J.C. Protein arrays: recent achievements and their application 
to study the human proteome. Curr. Proteomics 2013, in press. 
13. Mishra, S. Computational prediction of protein-protein complexes. BMC Res. Notes 2012, 5, e495. 
14. Jessulat, M.; Pitre, S.; Gui, Y.; Hooshyar, M.; Omidi, K.; Samanfar, B.; Tan le, H.; Alamgir, M.; 
Green, J.; Dehne, F.; et al. Recent advances in protein-protein interaction prediction: Experimental 
and computational methods. Expert Opin. Drug Discov. 2011, 6, 921–935. 
15. Xia, J.F.; Wang, S.L.; Lei, Y.K. Computational methods for the prediction of protein-protein 
interactions. Protein Pept. Lett. 2010, 17, 1069–1078. 
16. Skrabanek, L.; Saini, H.K.; Bader, G.D.; Enright, A.J. Computational prediction of protein-
protein interactions. Mol. Biotechnol. 2008, 38, 1–17. 
17. Pitre, S.; Alamgir, M.; Green, J.R.; Dumontier, M.; Dehne, F.; Golshani, A. Computational 
methods for predicting protein-protein interactions. Adv. Biochem. Eng. Biotechnol. 2008, 110, 
247–267. 
18. Keskin, O.; Tuncbag, N.; Gursoy, A. Characterization and prediction of protein interfaces to infer 
protein-protein interaction networks. Curr. Pharm. Biotechnol. 2008, 9, 67–76. 
19. Gomez, S.M.; Choi, K.; Wu, Y. Prediction of protein-protein interaction networks. Curr. Protoc. 
Bioinformatics 2008, doi:10.1002/0471250953.bi0802s22. 
20. Fernandez-Suarez, X.M.; Galperin, M.Y. The 2013 Nucleic Acids Research Database Issue and 
the online molecular biology database collection. Nucleic Acids Res. 2013, 41, D1–D7. 
21. Elefsinioti, A.; Sarac, O.S.; Hegele, A.; Plake, C.; Hubner, N.C.; Poser, I.; Sarov, M.; Hyman, A.; 
Mann, M.; Schroeder, M.; et al. Large-scale de novo prediction of physical protein-protein 
association. Mol. Cell. Proteomics 2011, 10, doi:10.1074/mcp.M111.010629. 
22. Klingstrom, T.; Plewczynski, D. Protein-protein interaction and pathway databases, a graphical 
review. Brief. Bioinform. 2011, 12, 702–713. 
23. Aranda, B.; Blankenburg, H.; Kerrien, S.; Brinkman, F.S.; Ceol, A.; Chautard, E.; Dana, J.M.; De 
Las Rivas, J.; Dumousseau, M.; Galeota, E.; et al. PSICQUIC and PSISCORE: Accessing and 
scoring molecular interactions. Nat. Methods 2011, 8, 528–529. 
24. Blankenburg, H.; Finn, R.D.; Prlic, A.; Jenkinson, A.M.; Ramirez, F.; Emig, D.; Schelhorn, S.E.; 
Buch, J.; Lengauer, T.; Albrecht, M. DASMI: Exchanging, annotating and assessing molecular 
interaction data. Bioinformatics 2009, 25, 1321–1328. 
25. Garcia-Garcia, J.; Schleker, S.; Klein-Seetharaman, J.; Oliva, B. BIPS: BIANA Interolog 
Prediction Server. A tool for protein-protein interaction inference. Nucleic Acids Res. 2012, 40, 
W147–W151. 
26. Schleker, S.; Sun, J.; Raghavan, B.; Srnec, M.; Muller, N.; Koepfinger, M.; Murthy, L.; Zhao, Z.; 
Klein-Seetharaman, J. The current Salmonella-host interactome. Proteomics Clin. Appl. 2012, 6, 
117–133. 
27. Orchard, S. Molecular interaction databases. Proteomics 2012, 12, 1656–1662. 
Proteomes 2013, 1 22 
 
  
28. National Center for Biotechnology Information. Available online: www.ncbi.nlm.nih.gov/gene. 
(accessed on 23 May 2013). 
29. Alzheimer and neuronal disease laboratory_data repository. Available online: 
www.cnb.csic.es/~naranjo/ (accessed on 23 May 2013). 
30. Uniprot protein knowledgebase/Swiss-Prot. Available online: http://www.uniprot.org/uniprot/ 
(accessed on 16 May 2013). 
31. UniProt Frequently Asked Questions_question_48. Available online: http://www.uniprot.org/faq/48 
(accessed on 23 May 2013). 
32. Uniprot link to CHKA_HUMAN, P35790, Choline kinase. Available online: 
http://www.uniprot.org/uniprot/P35790 (accessed on 23 May 2013). 
33. Dubois, T.; Howell, S.; Zemlickova, E.; Aitken, A. Identification of casein kinase Ialpha 
interacting protein partners. FEBS Lett. 2002, 517, 167–171. 
34. Szklarczyk, D.; Franceschini, A.; Kuhn, M.; Simonovic, M.; Roth, A.; Minguez, P.; Doerks, T.; 
Stark, M.; Muller, J.; Bork, P.; et al. The STRING database in 2011: Functional interaction 
networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011, 39, D561–D568. 
35. String 9.05_web interface. Available online: http://string-db.org/ (accessed on 23 May 2013). 
36. Psicquic View_web interface. Available online: http://www.ebi.ac.uk/Tools/webservices/ 
psicquic/view/main.xhtml (accessed on 23 May 2013). 
37. Casado-Vela, J.; Cebrian, A.; Gomez del Pulgar, M.T.; Lacal, J.C. Approaches for the study of 
cancer: Towards the integration of genomics, proteomics and metabolomics. Clin. Transl. Oncol. 
2011, 13, 617–628. 
38. UniProt Frequently Asked Questions_question_6. Available online: www.uniprot.org/faq/6 
(accessed on 23 May 2013). 
39. Gene Symbol Redundancy Checker. Available online: https://dl.dropboxusercontent.com/u/ 
77276631/SymbolRedundancy.zip (accessed on 23 May 2013). 
40. Swiss-Prot incorporated the International Protein Index Database. Available online: 
http://www.uniprot.org/news/2011/05/03/release (accessed on 23 May 2013). 
41. Navarro-Munoz, M.; Ibernon, M.; Bonet, J.; Perez, V.; Pastor, M.C.; Bayes, B.; Casado-Vela, J.; 
Navarro, M.; Ara, J.; Espinal, A.; et al. Uromodulin and alpha(1)-antitrypsin urinary peptide 
analysis to differentiate glomerular kidney diseases. Kidney Blood Press. Res. 2012, 35, 314–325. 
42. Tamm, I.; Horsfall, F.L., Jr. A mucoprotein derived from human urine which reacts with 
influenza, mumps, and Newcastle disease viruses. J. Exp. Med. 1952, 95, 71–97. 
43. Klein, J.; Jupp, S.; Moulos, P.; Fernandez, M.; Buffin-Meyer, B.; Casemayou, A.; Chaaya, R.; 
Charonis, A.; Bascands, J.L.; Stevens, R.; et al. The KUPKB: A novel Web application to access 
multiomics data on kidney disease. FASEB J. 2012, 26, 2145–2153. 
44. Casado-Vela, J.; del Pulgar, T.G.; Cebrian, A.; Alvarez-Ayerza, N.; Lacal, J.C. Human urine 
proteomics: Building a list of human urine cancer biomarkers. Expert Rev. Proteomics 2011, 8, 
347–360. 
45. Hegde, S.R.; Manimaran, P.; Mande, S.C. Dynamic changes in protein functional linkage 
networks revealed by integration with gene expression data. PLoS Comput. Biol. 2008, 4, 
e1000237. 
Proteomes 2013, 1 23 
 
  
46. Buxbaum, J.D.; Choi, E.K.; Luo, Y.; Lilliehook, C.; Crowley, A.C.; Merriam, D.E.; Wasco, W. 
Calsenilin: A calcium-binding protein that interacts with the presenilins and regulates the levels of 
a presenilin fragment. Nat. Med. 1998, 4, 1177–1181. 
47. Carrion, A.M.; Link, W.A.; Ledo, F.; Mellstrom, B.; Naranjo, J.R. DREAM is a Ca
2+
-regulated 
transcriptional repressor. Nature 1999, 398, 80–84. 
48. An, W.F.; Bowlby, M.R.; Betty, M.; Cao, J.; Ling, H.P.; Mendoza, G.; Hinson, J.W.; Mattsson, K.I.; 
Strassle, B.W.; Trimmer, J.S.; Rhodes, K.J. Modulation of A-type potassium channels by a family 
of calcium sensors. Nature 2000, 403, 553–556. 
49. Mellstrom, B.; Naranjo, J.R. Ca
2+
-dependent transcriptional repression and derepression: 
DREAM, a direct effector. Semin. Cell Dev. Biol. 2001, 12, 59–63. 
50. Pathguide.org. Available online: http://www.pathguide.org/ (accessed on 23 May 2013). 
51. Rivas, M.; Villar, D.; Gonzalez, P.; Dopazo, X.M.; Mellstrom, B.; Naranjo, J.R. Building the 
DREAM interactome. Sci. China Life Sci. 2011, 54, 786–792. 
52. Fedrizzi, L.; Lim, D.; Carafoli, E.; Brini, M. Interplay of the Ca
2+
-binding protein DREAM with 
presenilin in neuronal Ca
2+
 signaling. J. Biol. Chem. 2008, 283, 27494–27503. 
53. Ledo, F.; Carrion, A.M.; Link, W.A.; Mellstrom, B.; Naranjo, J.R. DREAM-alphaCREM 
interaction via leucine-charged domains derepresses downstream regulatory element-dependent 
transcription. Mol. Cell. Biol. 2000, 20, 9120–9126. 
54. Rivas, M.; Aurrekoetxea, K.; Mellstrom, B.; Naranjo, J.R. Redox signaling regulates 
transcriptional activity of the Ca
2+
-dependent repressor DREAM. Antioxid. Redox Signal. 2011, 
14, 1237–1243. 
55. Ledo, F.; Kremer, L.; Mellstrom, B.; Naranjo, J.R. Ca
2+
-dependent block of CREB-CBP 
transcription by repressor DREAM. EMBO J. 2002, 21, 4583–4592. 
56. Rivas, M.; Mellstrom, B.; Naranjo, J.R.; Santisteban, P. Transcriptional repressor DREAM 
interacts with thyroid transcription factor-1 and regulates thyroglobulin gene expression. J. Biol. 
Chem. 2004, 279, 33114–33122. 
57. Scsucova, S.; Palacios, D.; Savignac, M.; Mellstrom, B.; Naranjo, J.R.; Aranda, A. The repressor 
DREAM acts as a transcriptional activator on Vitamin D and retinoic acid response elements. 
Nucleic Acids Res. 2005, 33, 2269–2279. 
58. Lusin, J.D.; Vanarotti, M.; Li, C.; Valiveti, A.; Ames, J.B. NMR structure of DREAM: 
Implications for Ca(2+)-dependent DNA binding and protein dimerization. Biochemistry 2008, 
47, 2252–2264. 
59. Zaidi, N.F.; Kuplast, K.G.; Washicosky, K.J.; Kajiwara, Y.; Buxbaum, J.D.; Wasco, W. 
Calsenilin interacts with transcriptional co-repressor C-terminal binding protein(s). J. Neurochem. 
2006, 98, 1290–1301. 
60. Ruiz-Gomez, A.; Mellstrom, B.; Tornero, D.; Morato, E.; Savignac, M.; Holguin, H.; 
Aurrekoetxea, K.; Gonzalez, P.; Gonzalez-Garcia, C.; Cena, V.; et al. G protein-coupled receptor 
kinase 2-mediated phosphorylation of downstream regulatory element antagonist modulator regulates 
membrane trafficking of Kv4.2 potassium channel. J. Biol. Chem. 2007, 282, 1205–1215. 
61. Quintero, C.A.; Valdez-Taubas, J.; Ferrari, M.L.; Haedo, S.D.; Maccioni, H.J. Calsenilin and 
CALP interact with the cytoplasmic tail of UDP-Gal:GA2/GM2/GD2 beta-1,3-galactosyltransferase. 
Biochem. J. 2008, 412, 19–26. 
Proteomes 2013, 1 24 
 
  
62. Rivas, M.; Mellstrom, B.; Torres, B.; Cali, G.; Ferrara, A.M.; Terracciano, D.; Zannini, M.; 
Morreale de Escobar, G.; Naranjo, J.R. The DREAM protein is associated with thyroid 
enlargement and nodular development. Mol. Endocrinol. 2009, 23, 862–870. 
63. Wu, L.J.; Mellstrom, B.; Wang, H.; Ren, M.; Domingo, S.; Kim, S.S.; Li, X.Y.; Chen, T.; 
Naranjo, J.R.; Zhuo, M. DREAM (downstream regulatory element antagonist modulator) 
contributes to synaptic depression and contextual fear memory. Mol. Brain 2010, 3, e3. 
64. Anderson, D.; Mehaffey, W.H.; Iftinca, M.; Rehak, R.; Engbers, J.D.; Hameed, S.; Zamponi, G.W.; 
Turner, R.W. Regulation of neuronal activity by Cav3-Kv4 channel signaling complexes.  
Nat. Neurosci. 2010, 13, 333–337. 
65. Zhang, Y.; Su, P.; Liang, P.; Liu, T.; Liu, X.; Liu, X.Y.; Zhang, B.; Han, T.; Zhu, Y.B.;  
Yin, D.M.; et al. The DREAM protein negatively regulates the NMDA receptor through 
interaction with the NR1 subunit. J. Neurosci. 2010, 30, 7575–7586. 
66. Palczewska, M.; Casafont, I.; Ghimire, K.; Rojas, A.M.; Valencia, A.; Lafarga, M.; Mellstrom, B.; 
Naranjo, J.R. Sumoylation regulates nuclear localization of repressor DREAM. Biochim. Biophys. 
Acta 2011, 1813, 1050–1058. 
67. Ramachandran, P.L.; Craig, T.A.; Atanasova, E.A.; Cui, G.; Owen, B.A.; Bergen, H.R., 3rd; Mer, G.; 
Kumar, R. The potassium channel interacting protein 3 (DREAM/KChIP3) heterodimerizes with 
and regulates calmodulin function. J. Biol. Chem. 2012, 287, 39439–39448. 
68. Full list of human genes, acronyms and descriptions (NCBI). Available online: 
ftp://ftp.ncbi.nih.gov/gene/DATA/GENE_INFO/Mammalia/ (accessed on 23 May 2013). 
69. DASMI_web interface. Available online: http://dasmi.de/dasmiweb.php (accessed on 23 May 2013).  
70. BIPS_web interface. Available online: http://sbi.imim.es/web/index.php/research/servers/bips. 
(accessed on 23 May 2013). 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
